Activity of fulvestrant in HER2-overexpressing advanced breast cancer

Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only ∼15% of pat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2010-06, Vol.21 (6), p.1246-1253
Hauptverfasser:	Robertson, J.F.R., Steger, G.G., Neven, P., Barni, S., Gieseking, F., Nolè, F., Pritchard, K.I., O'Malley, F.P., Simon, S.D., Kaufman, B., Petruzelka, L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult advanced breast cancer Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Carcinoma - drug therapy Carcinoma - metabolism Chemotherapy, Adjuvant Disease Progression Estradiol - administration & dosage Estradiol - adverse effects Estradiol - analogs & derivatives Estradiol - pharmacology Estradiol - therapeutic use Faslodex Female Fulvestrant Gynecology. Andrology. Obstetrics HER2 human epidermal growth factor 2 Humans Mammary gland diseases Medical sciences Middle Aged Models, Biological Neoadjuvant Therapy Pharmacology. Drug treatments Receptor, ErbB-2 - metabolism Retrospective Studies Treatment Outcome Tumors Up-Regulation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!